Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie chłoniaka (Hodgkina lub innego typu) potwierdzone badaniem histopatologicznym
- •Wiek co najmniej 20 lat
- •Kwalifikacja do systemowego leczenia chemioterapią w celu całkowitego wyleczenia
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Nowotwory szpiku kostnego (chłoniakom szpikowe)
- •Szpiczak plazmocytowy
- •Pacjenci, którzy nie wymagają systemowego leczenia chemioterapią w celu wyleczenia
Simplified criteria — AI translation
Trial details
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Samsung Medical Center
Seoul, South Korea
Trial contact
Seok Jin Kim, MD., PhD.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.